Patent ID: 11965022
Assignee: SANA BIOTECHNOLOGY, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 1:
2. A pharmaceutical composition comprising:
(i) a population of engineered primary T cells comprising reduced expression of HLA-A, HLA-B, HLA-C, HLA-DP, HLA-DQ, HLA-DR, B2M, CIITA, TCR-alpha, and/or TCR-beta relative to a wild-type cell or a control cell, wherein the population of engineered primary T cells comprise a set of exogenous polynucleotides comprising a first exogenous polynucleotide encoding CD47 and a second exogenous polynucleotide encoding a chimeric antigen receptor (CAR), wherein the first and/or second exogenous polynucleotides are inserted into at least one allele of the cell,
(ii) a base solution, and
(iii) one or more cryoprotective agents.